Morgenthaler's Life Sciences Renewal
This article was originally published in Start Up
Morgenthaler Ventures, biotech, medical device, and communications/computer technology investors since the mid-'80s, backed away from the biotech group in 1993. But the investment pendulum has now swung away from IT and toward health care. So the firm is back into biotech investing, and is also picking up the pace in devices.
You may also be interested in...
The notion of incubators is catching on quickly in medical devices, thanks in part to a difficult financing climate and, in part, to the desire of some executives to find a new career path, focused on mentoring companies and leveraging skill sets across a number of projects at once. Designed primarily to get early stage product ideas to proof of principle quickly, incubators are overcoming skepticism about their proper role and beginning to make their mark on the device industry. In this two-part series, we look at several different incubator models
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.